Cargando…
Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate that specifically targets HER2 thanks to its antibody component trastuzumab. In spite of responses to this novel agent, acquired resistance to treatment remains a major obstacle. Prolonged in vitro exposure of the gastroesophageal junction...
Autores principales: | Sauveur, Juliette, Matera, Eva-Laure, Chettab, Kamel, Valet, Philippe, Guitton, Jerome, Savina, Ariel, Dumontet, Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940380/ https://www.ncbi.nlm.nih.gov/pubmed/29765526 http://dx.doi.org/10.18632/oncotarget.24975 |
Ejemplares similares
-
Characterization of T‐DM1‐resistant breast cancer cells
por: Sauveur, Juliette, et al.
Publicado: (2020) -
Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity
por: Duong, Minh Ngoc, et al.
Publicado: (2015) -
Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding
por: Hirz, Taghreed, et al.
Publicado: (2017) -
Transcriptional and Metabolic Investigation in 5′-Nucleotidase Deficient Cancer Cell Lines
por: Cadassou, Octavia, et al.
Publicado: (2021) -
A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
por: Chettab, Kamel, et al.
Publicado: (2023)